In a 28‑year‑old woman with a space‑occupying brain lesion who is now experiencing bradycardic episodes while on levetiracetam and dexamethasone, how should we evaluate and manage the bradycardia?

Evaluation and Management of Bradycardia in a Patient with Space-Occupying Brain Lesion

Immediate Priority: Assess for Elevated Intracranial Pressure

Bradycardia in the setting of a space-occupying brain lesion is elevated intracranial pressure (ICP) until proven otherwise—this is a neurosurgical emergency requiring immediate neuroimaging and neurosurgical consultation. 1

• The combination of hypertension, bradycardia, and irregular respirations (Cushing's triad) indicates critically elevated ICP, though all three components may not be present simultaneously. 1
• Bradycardia in a patient with neurologic injury should immediately raise suspicion for elevated ICP and potential herniation, even if other components of Cushing's triad are absent. 1
• ICP >20–25 mmHg is considered elevated and requires aggressive therapy; ICP between 20–40 mmHg is associated with a 3.95 times higher mortality risk, while ICP >40 mmHg increases mortality risk 6.9-fold. 1

Immediate Interventions for Suspected Elevated ICP

• Elevate the head of bed to 20–30 degrees. 1
• Ensure adequate oxygenation and ventilation. 1
• Administer mannitol 0.5–1 g/kg IV as first-line osmotic therapy. 1, 2
• Obtain urgent neuroimaging (CT or MRI) to assess for mass effect, midline shift, or herniation. 1
• Neurosurgical consultation is mandatory; surgical decompression is the primary treatment for focal lesions causing brain compression. 2

Secondary Consideration: Drug-Induced Bradycardia

Levetiracetam and Bradycardia

• Levetiracetam is not typically associated with bradycardia as a direct adverse effect; the most serious adverse effects are behavioral in nature. 3, 4
• Levetiracetam lacks cytochrome P450 enzyme-inducing potential and is not associated with clinically significant pharmacokinetic interactions with other drugs. 3
• The drug has a favorable safety profile with treatment-emergent adverse events broadly similar to placebo, most being mild to moderate in severity. 3, 5

Dexamethasone and Bradycardia

• Dexamethasone itself is not a recognized cause of bradycardia. 6
• However, the withdrawal of dexamethasone in this patient may have unmasked elevated ICP by removing the anti-edema effect of corticosteroids around the brain lesion. 2, 7
• Corticosteroids are effective in reducing vasogenic edema around brain tumors but are contraindicated in traumatic cerebral edema. 2

Systematic Evaluation Algorithm

Step 1: Determine if Bradycardia is Symptomatic

• Symptomatic bradycardia is defined as documented bradyarrhythmia directly causing syncope, presyncope, dizziness, altered mental status, chest pain, dyspnea, hypotension, or heart failure symptoms. 6, 8
• Asymptomatic bradycardia (even with rates as low as 37–40 bpm) requires no treatment and has a benign prognosis. 6, 8
• In this patient, altered mental status or hemodynamic compromise would indicate symptomatic bradycardia requiring intervention. 8

Step 2: Obtain 12-Lead ECG and Identify Rhythm

• Document rhythm, rate, PR interval, QRS duration, and bundle-branch block patterns. 6, 8
• Classify as sinus bradycardia, sinus node dysfunction, or atrioventricular block. 6, 9
• Sinus bradycardia is defined as sinus rate <50 bpm with normal P-wave morphology. 9

Step 3: Rule Out Reversible Causes (Class I Priority)

Reversible Cause	Evaluation	Treatment
Elevated ICP	Neuroimaging, neurologic exam	Neurosurgical consultation, mannitol, head elevation [1,2]
Medications (β-blockers, CCBs, digoxin, amiodarone)	Review drug list	Discontinue or reduce dose [6,8]
Hypothyroidism	TSH, free T4	Levothyroxine replacement [6,8]
Electrolyte abnormalities	Serum K⁺, Mg²⁺	Correct hypo-/hyperkalemia, hypomagnesemia [6,8]
Hypoxemia	Pulse oximetry, ABG	Supplemental oxygen [9]
Acute MI (especially inferior)	Troponin, ECG	Treat ischemia [6,8]

Step 4: Acute Pharmacologic Management (Only if Symptomatic)

• Atropine 0.5–1 mg IV bolus is first-line for symptomatic bradycardia; repeat every 3–5 minutes up to a total of 3 mg. 6, 8
• Doses <0.5 mg may paradoxically worsen bradycardia. 6, 8
• Absolute contraindication: Do not give atropine to heart-transplant recipients without autonomic re-innervation. 6, 8

Step 5: Temporary Pacing (Bridge Therapy)

• Transcutaneous pacing is indicated for severe symptoms or hemodynamic compromise unresponsive to atropine, serving as a bridge to transvenous or permanent pacing. 6, 8
• Transvenous pacing is indicated for persistent instability refractory to medical therapy. 6, 8

Step 6: Permanent Pacemaker Consideration

• Permanent pacing is indicated (Class I) when symptomatic bradycardia persists after reversible causes have been excluded or adequately treated. 6, 8
• Do not implant a permanent pacemaker before fully evaluating and correcting reversible causes, especially elevated ICP in this patient. 6, 8

Critical Pitfalls to Avoid

• Do not attribute bradycardia to levetiracetam without first excluding elevated ICP, which is the most likely cause in a patient with a space-occupying brain lesion. 1, 3
• Do not treat asymptomatic bradycardia based solely on heart-rate numbers. 6, 8
• Do not delay neurosurgical evaluation when bradycardia occurs in the setting of a brain lesion; this is a medical emergency. 1, 2
• Do not administer atropine doses <0.5 mg, which may worsen bradycardia. 6, 8
• Do not proceed to permanent pacing before addressing the underlying brain lesion and elevated ICP. 6, 8

Prognosis and Follow-Up

• Bradycardia associated with elevated ICP typically resolves after treatment of the underlying cause (surgical decompression or medical management of ICP). 6, 1
• If bradycardia persists after ICP normalization and all reversible causes have been excluded, permanent pacing may be considered. 6, 8
• Asymptomatic bradycardia has a benign prognosis and does not affect survival. 6, 8